TPCW
NVO

TD Private Client Wealth’s Novo Nordisk NVO Stock Holding History

TD Private Client Wealth’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208K Sell
5,666
-7,397
-57% -$350K ﹤0.01% 639
2025
Q4 		$665K Buy
13,063
+6,343
+94% +$324K 0.01% 420
2025
Q3 		$373K Buy
6,720
+4,140
+160% +$242K 0.01% 536
2025
Q2 		$178K Sell
2,580
-331
-11% -$22.5K ﹤0.01% 661
2025
Q1 		$202K Sell
2,911
-103
-3% -$8.51K 0.01% 593
2024
Q4 		$259K Sell
3,014
-1,544
-34% -$167K 0.01% 550
2024
Q3 		$543K Sell
4,558
-358
-7% -$47.7K 0.02% 444
2024
Q2 		$702K Sell
4,916
-2,240
-31% -$297K 0.02% 396
2024
Q1 		$919K Sell
7,156
-6,115
-46% -$728K 0.03% 360
2023
Q4 		$1.37M Sell
13,271
-3,032
-19% -$300K 0.05% 286
2023
Q3 		$1.48M Buy
16,303
+1,781
+12% +$157K 0.06% 257
2023
Q2 		$1.18M Buy
14,522
+6,622
+84% +$541K 0.05% 304
2023
Q1 		$629K Sell
7,900
-1,934
-20% -$137K 0.03% 399
2022
Q4 		$665K Sell
9,834
-286
-3% -$16.8K 0.03% 382
2022
Q3 		$504K Sell
10,120
-120
-1% -$6.43K 0.03% 402
2022
Q2 		$571K Buy
10,240
+4,846
+90% +$269K 0.03% 394
2022
Q1 		$300K Sell
5,394
-924
-15% -$47.4K 0.01% 495
2021
Q4 		$354K Buy
6,318
+234
+4% +$12.7K 0.01% 470
2021
Q3 		$292K Buy
6,084
+2,078
+52% +$100K 0.01% 477
2021
Q2 		$168K Sell
4,006
-382
-9% -$14.8K 0.01% 545
2021
Q1 		$148K Sell
4,388
-700
-14% -$24.9K 0.01% 545
2020
Q4 		$178K Sell
5,088
-3,782
-43% -$131K 0.01% 495
2020
Q3 		$308K Sell
8,870
-1,502
-14% -$50.1K 0.02% 411
2020
Q2 		$340K Sell
10,372
-6,230
-38% -$199K 0.02% 393
2020
Q1 		$500K Buy
16,602
+3,892
+31% +$116K 0.04% 321
2019
Q4 		$368K Buy
+12,710
New +$352K 0.02% 388

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

TD Private Client Wealth's NVO Position: Q1 2026 in Review

TD Private Client Wealth reduced its Novo Nordisk (NVO) stake by 57% in Q1 2026, selling an estimated $350K and leaving 5,666 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #639.

TD Private Client Wealth first reported a position in NVO in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.48M in Q3 2023. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • TD Private Client Wealth held 5,666 shares of Novo Nordisk worth $208K as of Q1 2026.
  • TD Private Client Wealth sold 7,397 Novo Nordisk shares in Q1 2026, an estimated $350K.
  • Novo Nordisk made up ﹤0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #639 holding.
  • TD Private Client Wealth first reported a position in Novo Nordisk in Q4 2019 and has held it in 26 quarters since.
  • TD Private Client Wealth's Novo Nordisk position peaked at $1.48M in Q3 2023.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.